Services to evaluate the circulating biomarkers in cancer to support dceg's efforts to conduct epidemiologic studies in relation to cancer.
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N91021D00001
- Awardee
-
Olink Proteomics AB UEI SC7KUWJQ7MY5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 5 $274,790 obligated
Award facts
- Opportunity
-
- Notice of Intent to Sole-Source: Services Supporting the Evaluation of Circulating Biomarkers in Cancer Special Notice · 75N91020Q00065 · Posted Jun 9, 2020
- Combined order value
- $274,790 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 39% used
- $699,900.00
- Award type
- Single award
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institutes of Health National Cancer Institute awarded a single award indefinite delivery contract to Olink Proteomics AB to procure protein biomarker analysis services. Task orders issued to date against the contract include immuno-oncology, inflammation, and pediatric oncology analysis services using Olink's proprietary multiplex platforms. Services are being performed in various locations including Massachusetts, Maryland, and the District of Columbia through July 2024. Collectively the task orders are valued at approximately $700,000.
The originating solicitation sought statements of capability from Olink Proteomics AB on a sole-source basis to ensure data comparability with previous Division of Cancer Epidemiology and Genetics studies. The services to be acquired include aliquoting and testing circulating biomarkers in cancer patients to support the Division's epidemiological and genetic cancer research efforts.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Exercise an Option | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91021D00001?
75N91021D00001 was awarded to Olink Proteomics AB by National Cancer Institute (National Institutes of Health) on December 18, 2020.
How much is contract 75N91021D00001 worth?
Orders under 75N91021D00001 have obligated $274,790. 75N91021D00001's own ceiling is $699,900.
How many orders have been placed under contract 75N91021D00001?
5 orders have been placed under 75N91021D00001, the latest on August 1, 2023.
Who can order from contract 75N91021D00001?
75N91021D00001 is a single award indefinite delivery contract.
Was contract 75N91021D00001 competed?
The extent of competition for 75N91021D00001 was not competed under sap. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV